NO20060991L - Feksofenadinsammensetning og fremgangsmate til fremstilling - Google Patents

Feksofenadinsammensetning og fremgangsmate til fremstilling

Info

Publication number
NO20060991L
NO20060991L NO20060991A NO20060991A NO20060991L NO 20060991 L NO20060991 L NO 20060991L NO 20060991 A NO20060991 A NO 20060991A NO 20060991 A NO20060991 A NO 20060991A NO 20060991 L NO20060991 L NO 20060991L
Authority
NO
Norway
Prior art keywords
composition
pexophenadine
preparation
plasma
hexophenadine
Prior art date
Application number
NO20060991A
Other languages
English (en)
Norwegian (no)
Inventor
Indranil Nandi
Ashish Anilbhai Patel
Mohnsen Sadatrezael
Pablo Davila
Virendra Maheshappa Khanapure
Durendra Wasudeorao Durugkar
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO20060991L publication Critical patent/NO20060991L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20060991A 2003-07-31 2006-02-28 Feksofenadinsammensetning og fremgangsmate til fremstilling NO20060991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/631,874 US20050065183A1 (en) 2003-07-31 2003-07-31 Fexofenadine composition and process for preparing
PCT/EP2004/008600 WO2005013987A1 (en) 2003-07-31 2004-07-30 Fexofenadine composition and process for preparing

Publications (1)

Publication Number Publication Date
NO20060991L true NO20060991L (no) 2006-04-28

Family

ID=34135544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060991A NO20060991L (no) 2003-07-31 2006-02-28 Feksofenadinsammensetning og fremgangsmate til fremstilling

Country Status (12)

Country Link
US (1) US20050065183A1 (pt)
EP (1) EP1651218A1 (pt)
JP (1) JP2007500682A (pt)
AR (1) AR045193A1 (pt)
AU (1) AU2004262914A1 (pt)
BR (1) BRPI0413186A (pt)
CR (1) CR8220A (pt)
EC (1) ECSP066327A (pt)
NO (1) NO20060991L (pt)
RU (1) RU2006105720A (pt)
WO (1) WO2005013987A1 (pt)
ZA (1) ZA200600519B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158334A0 (en) * 2001-04-09 2004-05-12 Teva Pharma Polymorphs of fexofenadine hydrochloride
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
JP2007532687A (ja) * 2004-04-26 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド フェキソフェナジン塩酸塩の結晶形およびその製造方法
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
CN101340896A (zh) * 2005-12-22 2009-01-07 特瓦制药工业有限公司 含有低溶解性药物的压缩的固体剂型和其制备方法
EP2037918A2 (en) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
CA2811634C (en) * 2010-09-21 2019-01-15 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
JP6040218B2 (ja) * 2012-02-23 2016-12-07 フロイント産業株式会社 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
JP6184727B2 (ja) * 2013-04-15 2017-08-23 ロート製薬株式会社 医薬組成物
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN106137989A (zh) * 2016-07-20 2016-11-23 南通雅本化学有限公司 一种基于盐酸非索非那定的药物组合物
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
JP6410895B2 (ja) * 2017-07-26 2018-10-24 ロート製薬株式会社 医薬組成物
JP2019011350A (ja) * 2018-09-25 2019-01-24 ロート製薬株式会社 医薬組成物
WO2022123511A1 (en) * 2020-12-11 2022-06-16 Cellix Bio Private Limited A composition comprising fexofenadine
GB2629127A (en) 2022-08-31 2024-10-23 Novumgen Ltd An orodispersible tablet of fexofenadine and its process of preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
JPS52151717A (en) * 1976-06-09 1977-12-16 Shionogi & Co Ltd Sugar coating on solid preparations
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
JPS6183123A (ja) * 1984-09-28 1986-04-26 Taisho Pharmaceut Co Ltd 抗喘息剤
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
CA2134211C (en) * 1992-05-11 1999-06-29 James K. Woodward Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
EP1369409B1 (en) * 1993-06-24 2006-04-05 AMR Technology, Inc. Process for preparing compounds useful as intermediates
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH09315971A (ja) * 1996-05-28 1997-12-09 Daito Kk テルフェナジン含有錠剤製剤
ATE503472T1 (de) * 1996-11-15 2011-04-15 Ajinomoto Kk Nateglinide-tablettenzubereitungen
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
AU2199500A (en) * 1998-12-23 2000-07-31 Alza Corporation Gastric retention dosage form having multiple layers
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine

Also Published As

Publication number Publication date
ZA200600519B (en) 2007-01-31
BRPI0413186A (pt) 2006-10-03
WO2005013987A1 (en) 2005-02-17
EP1651218A1 (en) 2006-05-03
AU2004262914A1 (en) 2005-02-17
AR045193A1 (es) 2005-10-19
JP2007500682A (ja) 2007-01-18
RU2006105720A (ru) 2007-09-10
ECSP066327A (es) 2006-07-28
US20050065183A1 (en) 2005-03-24
CR8220A (es) 2006-07-27

Similar Documents

Publication Publication Date Title
NO20060991L (no) Feksofenadinsammensetning og fremgangsmate til fremstilling
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
NO20100569L (no) Farmasoytiske formuleringer og anvendelse derav i forebyggelsen av slag, diabetes og/eller kongestivt hjertesvikt
NO20071354L (no) anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.
NO20081889L (no) Fast vaksine formulering
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
WO1999033792A3 (en) Prodrugs os aspartyl protease inhibitors
NO2017063I1 (no) Kombinasjon av: - rilpivirine hydroklorid etter en terapeutisk ekvivalent form derav, - emtricitabine og - tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
NO20050018L (no) Lasofoxifentabletter og belegg
MX2023009833A (es) Formulaciones farmaceuticas de cetanafadina y metodos para prepararlas y utlizarlas.
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
SE0102440D0 (sv) New compound
DE60215129D1 (de) Esmolol-enthaltende zubereitungen